SARS-CoV-2 natural infection, but not vaccine-induced immunity, elicits cross-reactive immunity to OC43
- PMID: 39391514
- PMCID: PMC11466580
- DOI: 10.1016/j.heliyon.2024.e37928
SARS-CoV-2 natural infection, but not vaccine-induced immunity, elicits cross-reactive immunity to OC43
Abstract
Background: The recent SARS-CoV-2 pandemic renewed interest toward other non-severe acute respiratory syndrome human coronaviruses. Among these, OC43 is a seasonal human coronavirus widely diffused in the population (90 % seroprevalence in adults) which is responsible for mild respiratory symptoms. As OC43 protective immunity is short lasting, we investigated whether humoral immunity to SARS-CoV-2, induced by vaccination or spontaneous infection, protects against OC43 re-infection at either systemic or mucosal level.
Methods: A neutralization assay was conducted against "wild type" SARS-CoV-2 lineage B.1 (EU) and OC43 in VeroE6 cell lines using plasma and saliva samples from 49 subjects who were never infected and received three BNT162b2 RNA vaccine doses (SARS-CoV-2-vaccinated: SV) and from 25 SARS-CoV-2-infected and vaccinated subjects (SIV). The assays were performed right before (T0), fifteen days (T1) and three months (T2) after the third dose administration (SV) or post-infection (SIV).
Results: After the third vaccination dose was administered, SARS-CoV-2-specific neutralizing activity (NA) significantly augmented in SV saliva (p < 0.05) and plasma (p < 0.0001); yet, this NA was not protective against OC43. Conversely, in SIV, at T1, natural infection significantly increased NA against both SARS-CoV-2 (p < 0.01) and OC43 (p < 0.05) at systemic as well as mucosal level; still, this cross-reactivity vanished at T2. Of note, NA against SARS-CoV-2 and OC43 was shown to be higher in SIV compared to SV in plasma and saliva, as well; though, statistically significant differences were evident only in the oral mucosa at T1 (p < 0.05).
Conclusions: Our findings show that SARS-CoV-2 spontaneous infection triggers a more comprehensive and cross-reactive immunity than vaccine-induced immunity, protecting against OC43 at the systemic and mucosal levels. These results support the development of a pan-coronavirus vaccine able to prompt cross-reactive immunity even against seasonal coronaviruses, which could have enormous economic and health benefits globally.
Keywords: Cross-reactive immunity; Human coronaviruses; Mucosal immunity; OC43; SARS-CoV-2.
© 2024 The Authors.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Similar articles
-
Saliva and Plasma Neutralizing Activity Induced by the Administration of a Third bnt162b2 Vaccine Dose.Int J Mol Sci. 2022 Nov 18;23(22):14341. doi: 10.3390/ijms232214341. Int J Mol Sci. 2022. PMID: 36430815 Free PMC article.
-
Natural SARS-CoV-2 Infection Affects Neutralizing Activity in Saliva of Vaccinees.Front Immunol. 2022 Mar 11;13:820250. doi: 10.3389/fimmu.2022.820250. eCollection 2022. Front Immunol. 2022. PMID: 35359971 Free PMC article.
-
Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2.bioRxiv [Preprint]. 2022 Dec 1:2022.12.01.518643. doi: 10.1101/2022.12.01.518643. bioRxiv. 2022. Update in: PLoS Pathog. 2023 Jul 27;19(7):e1011032. doi: 10.1371/journal.ppat.1011032. PMID: 36482973 Free PMC article. Updated. Preprint.
-
Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel.Semin Immunol. 2021 Jun;55:101507. doi: 10.1016/j.smim.2021.101507. Epub 2021 Oct 25. Semin Immunol. 2021. PMID: 34716096 Free PMC article. Review.
-
Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study.Microorganisms. 2021 Jul 31;9(8):1643. doi: 10.3390/microorganisms9081643. Microorganisms. 2021. PMID: 34442723 Free PMC article. Review.
Cited by
-
Comprehensive analysis of human coronavirus antibody responses in ICU and non-ICU COVID-19 patients reveals IgG3 against SARS-CoV-2 spike protein as a key biomarker of disease severity.J Med Microbiol. 2025 May;74(5):002012. doi: 10.1099/jmm.0.002012. J Med Microbiol. 2025. PMID: 40359129 Free PMC article.
References
-
- Kapikian A.Z. The coronaviruses. Dev. Biol. Stand. 1975;28:42–64. - PubMed
-
- Cappelletti G., Colombrita C., Limanaqi F., Invernizzi S., Garziano M., Vanetti C., Moscheni C., Santangelo S., Zecchini S., Trabattoni D., et al. Human motor neurons derived from induced pluripotent stem cells are susceptible to SARS-CoV-2 infection. Front. Cell. Neurosci. 2023;17 doi: 10.3389/fncel.2023.1285836. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous